连续肾脏替代治疗在婴幼儿肝移植术后急性肾损伤中的应用
该回顾性研究纳入2019年1月1日至2021年6月1日天津市第一中心医院婴幼儿肝移植术后1年内发生急性肾损伤的患儿,按是否行连续肾脏替代治疗分为连续肾脏替代治疗组(18例)与非连续肾脏替代治疗组(171例)。连续肾脏替代治疗组肝移植时长8.8±1.5小时显著长于非连续肾脏替代治疗组7.5±1.3小时,术中出血量370(220-800)mL显著多于310(200-400)mL,术后并发症(非计划手术、原发性移植物无功能、再次移植、肝动脉血栓、肠瘘)发生率均显著更高(均P<0.05)。连续肾脏替代治疗平均启动时间10(1-240)天,人均治疗3.3(1.0-14.0)次,每次平均10.1(6.0-19.3)小时,血肌酐平均下降25.6%(13.5%-45.0%)。连续肾脏替代治疗组1年及2年生存率均为72.22%,非连续肾脏替代治疗组分别为97.1%和96.5%,差异均有统计学意义(均P<0.01)。作者认为连续肾脏替代治疗是清除炎症因子、维持循环与内环境稳定的有力手段,可有效改善多器官功能障碍。
要点
- 512例儿童肝移植中189例(36.9%)术后1年内发生急性肾损伤,其中18例行连续肾脏替代治疗、171例未行连续肾脏替代治疗。
- 连续肾脏替代治疗组肝移植时长8.8±1.5小时 vs 非连续肾脏替代治疗组7.5±1.3小时,术中出血量370(220-800)mL vs 310(200-400)mL,均显著更高。
- 连续肾脏替代治疗组术后非计划手术8例(44.4%)vs 14例(8.2%)、原发性移植物无功能1例(5.6%)vs 0例(0%)、再次移植3例(16.7%)vs 0例(0%)、肝动脉血栓3例(16.7%)vs 4例(2.3%)、肠瘘2例(11.1%)vs 2例(1.2%),均P<0.05。
- 连续肾脏替代治疗平均启动时间10(1-240)天,人均3.3(1.0-14.0)次,每次平均10.1(6.0-19.3)小时,血肌酐平均下降25.6%(13.5%-45.0%)。
- 连续肾脏替代治疗组1年及2年生存率均为72.22%,非连续肾脏替代治疗组1年97.1%、2年96.5%,差异均有统计学意义(均P<0.01)。
适用人群与场景
- 2019年1月1日至2021年6月1日天津市第一中心医院肝移植术后1年内发生急性肾损伤的婴幼儿。
- 按是否行连续肾脏替代治疗分为连续肾脏替代治疗组(18例)与非连续肾脏替代治疗组(171例)。
处置流程与药物剂量
- 连续肾脏替代治疗平均启动时间为术后10(1-240)天,人均治疗3.3(1.0-14.0)次,每次平均治疗10.1(6.0-19.3)小时。
- 连续肾脏替代治疗后血肌酐平均下降25.6%(13.5%-45.0%)。
红旗征与不能漏的情况
- 术后并发症:非计划手术连续肾脏替代治疗组8例(44.4%)vs 非连续肾脏替代治疗组14例(8.2%)。
- 原发性移植物无功能连续肾脏替代治疗组1例(5.6%)vs 非连续肾脏替代治疗组0例(0%)。
- 再次移植连续肾脏替代治疗组3例(16.7%)vs 非连续肾脏替代治疗组0例(0%)。
- 肝动脉血栓连续肾脏替代治疗组3例(16.7%)vs 非连续肾脏替代治疗组4例(2.3%)。
- 肠瘘连续肾脏替代治疗组2例(11.1%)vs 非连续肾脏替代治疗组2例(1.2%)。
研究设计与关键结果
- 回顾性研究:共512例儿童肝移植,189例(36.9%)术后1年内发生急性肾损伤,连续肾脏替代治疗组18例、非连续肾脏替代治疗组171例。
- 两组术前情况无显著差异;连续肾脏替代治疗组肝移植时长8.8±1.5小时 vs 非连续肾脏替代治疗组7.5±1.3小时,术中出血量370(220-800)mL vs 310(200-400)mL,均显著更高。
- 连续肾脏替代治疗组术后非计划手术8例(44.4%)vs 14例(8.2%)、原发性移植物无功能1例(5.6%)vs 0例(0%)、再次移植3例(16.7%)vs 0例(0%)、肝动脉血栓3例(16.7%)vs 4例(2.3%)、肠瘘2例(11.1%)vs 2例(1.2%),均P<0.05。
- 连续肾脏替代治疗平均启动时间10(1-240)天,人均治疗3.3(1.0-14.0)次,每次平均10.1(6.0-19.3)小时,血肌酐平均下降25.6%(13.5%-45.0%)。
- 连续肾脏替代治疗组死亡5例,1年及2年生存率均为72.22%;非连续肾脏替代治疗组死亡6例,1年生存率97.1%、2年生存率96.5%,差异均有统计学意义(均P<0.01)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为连续肾脏替代治疗是清除炎症因子、维持循环和内环境稳定的有力手段,可有效改善多器官功能障碍。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the clinical application of continuous renal replacement therapy (CRRT) in infants with acute kidney injury (AKI) after liver transplantation.
METHODS: A retrospective study was conducted on infants with AKI after liver transplantation in Tianjin First Center Hospital from January 1, 2019 to June 1, 2021. Infants with AKI within 1 year after liver transplantation were divided into CRRT group and non-CRRT group according to whether CRRT was performed. The preoperative and intraoperative condition, the postoperative complications were compared, the risk factors of CRRT for AKI infants, the clinical characteristics of CRRT were analyzed, and the prognosis between CRRT group and non-CRRT group were compared.
RESULTS: (1) A total of 512 cases of pediatric liver transplantation were performed. A total of 189 cases (36.9%) developed AKI within 1 year after surgery, including 18 cases in CRRT group and 171 cases in non-CRRT group. (2) There was no significant difference in preoperative conditions between the two groups. The duration of liver transplantation (hours: 8.8±1.5 vs. 7.5±1.3) and intraoperative blood loss [mL: 370 (220-800) vs. 310 (200-400)] in CRRT group were significantly higher than those in non-CRRT group. CRRT group had significantly higher incidence of postoperative complication [unplanned operation: 8 cases (44.4%) vs. 14 cases (8.2%), primary nonfunction: 1 case (5.6%) vs. 0 case (0%), retransplantation: 3 cases (16.7%) vs. 0 case (0%), hepatic artery thrombosis: 3 cases (16.7%) vs. 4 cases (2.3%), intestinal fistula: 2 cases (11.1%) vs. 2 cases (1.2%)] than non-CRRT group (all P < 0.05). (3) The average start time of CRRT was 10 (1-240) days. The per capita frequency of CRRT treatment was 3.3 (1.0-14.0) times. The average duration of each CRRT treatment was 10.1 (6.0-19.3) hours, the average reduction rate of serum creatinine (SCr) was 25.6% (13.5%-45.0%) after CRRT. (4) In CRRT group, 5 patients died, the 1-year and 2-year survival rates were both 72.22%. In non-CRRT group, 6 patients died, the 1-year and 2-year survival rates were 97.1% and 96.5%, respectively. There were significant differences in 1-year and 2-year survival rates between the two groups (both P < 0.01).
CONCLUSIONS: The incidence of AKI after pediatric liver transplantation was high, and most infants treated with CRRT were associated with serious surgical complications. CRRT was a powerful means to remove inflammatory factors and maintain the stability of circulation and internal environment, which could improve the multi-organ dysfunction effectively.
参考来源
- Sun Y, Wang B, Wang X, et al. [Application of continuous renal replacement therapy in infants with acute kidney injury after liver transplantation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35387721. doi:10.3760/cma.j.cn121430-20211109-01669
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。